Researchers at the University of Bayreuth have made significant progress in understanding the biosynthetic mechanism of fostriecin, a compound with potential anti-cancer properties.
Led by Prof. Dr. Frank Hahn, the team has successfully identified key enzymes involved in the production process, marking a first in this area of research.
These findings could have substantial implications for the scalability of fostriecin production, enhancing both yield and purity, which are critical for therapeutic applications.